BioPharmSignal logoBioPharmSignal

Biotech News

KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma

Immunocore Holdings plc (IMCR)Immunocore Holdings plcCompany update

IMCR (IMCR) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is imcr.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Related news

IMCRImmunocore Holdings plc2026-05-31 12:00 EST

Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma

IDYAIDEAYA Biosciences2026-06-01 15:00 EST

IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late-Breaking Oral Presentation at ASCO

REGNRegeneron Pharmaceuticals2026-05-16 00:19 EST

Regeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Metastatic Melanoma

IMCRImmunocore Holdings plc2026-05-06 11:00 EST

Immunocore reports first quarter financial results and provides a business update

INBXInhibrx2026-06-15 13:15 EST

Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma

RVMDRevolution Medicines2026-05-31 12:06 EST

Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer

LYELLyell Immunopharma2026-05-06 20:05 EST

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026

BMYBMYBristol-Myers Squibb Company2026-06-08 10:59 EST

Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease

REPLReplimune Group2026-05-31 12:00 EST

Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

REGNRegeneron Pharmaceuticals2026-05-21 21:01 EST

Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis

View all latest news

Immunocore Holdings plc

Immunocore is an immunotherapy company focused on T-cell receptor biology and oncology programs.

Recent company news

IMCRImmunocore Holdings plc2026-05-31 12:00 EST

Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma

IMCRImmunocore Holdings plc2026-05-06 11:00 EST

Immunocore reports first quarter financial results and provides a business update

IMCRImmunocore Holdings plc2026-04-19 22:00 EST

KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma

IMCRImmunocore Holdings plc2026-04-06 11:00 EST

Immunocore to present at the 25th Annual Needham Virtual Healthcare Conference

IMCRImmunocore Holdings plc2026-03-17 20:30 EST

Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting

Stock data

Close
33.77 USD
Market cap
1.5B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States